Wall Street Zen upgraded shares of Crescent Biopharma (NASDAQ:CBIO - Free Report) to a sell rating in a report released on Saturday morning.
Several other research firms have also weighed in on CBIO. TD Cowen upgraded shares of Crescent Biopharma to a "strong-buy" rating in a research report on Friday, June 20th. Stifel Nicolaus initiated coverage on Crescent Biopharma in a research report on Wednesday, June 25th. They set a "buy" rating and a $28.00 target price for the company. Finally, Lifesci Capital upgraded Crescent Biopharma to a "strong-buy" rating and set a $22.00 price target on the stock in a research note on Wednesday, June 18th. One investment analyst has rated the stock with a sell rating, two have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $25.67.
Get Our Latest Stock Analysis on CBIO
Crescent Biopharma Trading Down 9.2%
Shares of NASDAQ CBIO traded down $1.18 during trading hours on Friday, reaching $11.62. The stock had a trading volume of 144,291 shares, compared to its average volume of 31,179. The firm has a market capitalization of $227.17 million, a price-to-earnings ratio of -0.25 and a beta of 1.52. Crescent Biopharma has a twelve month low of $11.06 and a twelve month high of $63.00.
About Crescent Biopharma
(
Get Free Report)
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Further Reading
Before you consider Crescent Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.
While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
